ILD/IPF Lineup at ATS 2023


The ATS 2023 International Conference offers a robust scientific program highlighting the cutting-edge advancements in pulmonary, critical care, and sleep medicine. This includes several Postgraduate Courses, Scientific Symposia, and Meet the Expert Sessions addressing new developments and considerations in interstitial lung disease and idiopathic pulmonary fibrosis, as listed below. For more information on these and other sessions to be presented May 19–24 in Washington, DC, visit the online Program Itinerary.

  • PG4. State of the Art Management of Noninvasive Ventilation From Hospital to Ambulatory Care
  • PG7. Updates on Lung Transplantation; What Pulmonologists Need to Know?
  • PG8. Interstitial Lung Disease: Delivering Optimal, Patient Centered Care
  • PG13. Huffing and Puffing: Best Practice and State of the Art in CPET and PFT
  • A3. Fellows Case Conference
  • A7. The New ATS Clinical Practice Guidelines for Pulmonary Rehabilitation
  • A12. Publication to Empowerment — Transitioning Science into Environmental Justice Advocacy
  • A83. Great Cases: Clinical, Radiologic, and Pathologic Correlations by Master Clinicians
  • A86. Physical Fitness and Lung Health
  • A88. Neuro-Immune Interactions in Lung Development and Disease
  • A90. Myths or Truths: Controversies in Respiratory Medicine, the New Frontier
  • B9. Sex-Specific Mechanisms of Lung Disease Pathogenesis Through the Lens of Single Cell RNA Sequencing
  • B12. ATS Clinical Practice Guidelines: Clinical Practice on the Cutting Edge
  • B82. The Genetics of Interstitial Lung Disease: Current State and Future Promise
  • B85. Processing the Environment: Lung Lymphatics and Follicles in Disease
  • B91. Lung Aging: Why Your FEV1 Is Falling and Pneumonia Is Your Final Friend
  • C2. Endpoints for Therapeutic Trials in ILD
  • C11. Advancing Clinical Issues to ATS and Capitol Hill: The Oxygen Therapy Exemplar
  • C12. Immunology in Context: Mechanisms and Biomarkers that Determine Viral Disease Severity
  • C83. Pro/Con: Hot Topics in Interstitial Lung Disease
  • C86. Beyond the Transcriptome: How The Multi-“Omic” Universe Provides Novel Insights into IPF/ILD Pathogenesis
  • D2. Cough in Pulmonary Fibrosis — Annoying Symptom or Driver/Marker of Disease Progression?
  • D8. Under the Magnifying Glass: Omics and Deep Phenotyping in Pulmonary Vascular Diseases
  • D9. It’s About Time! The Circadian Clock in Lung Disease, From Bench to Bedside
  • D10. An Age-Friendly Framework for Caring for Older Adults with Chronic Lung Disease
  • D83. Establishing A Paradigm for Multidisciplinary Care in Sarcoidosis
  • D88. Beyond Bioenergetics: Cellular Metabolism in Lung Health and Disease
  • D89. OSA-Associated Inflammation and Comorbidities: Causes and Consequences
  • MTE1. Emerging Presentations of Illicit or Synthetic Drugs Toxicity
  • MTE4. Caring for Children Who Receive Hematopoietic Stem Cell Transplantation for Non-Malignant Indications
  • MTE7. Interstitial Lung Disease in Anca Vasculitis
  • MTE 11. Small Airways Disease: When It’s Not Asthma
  • MTE16. It Takes a Village: Integrating ILD Support Groups into Community Medical Centers
  • MTE19. Decentralized Clinical Trials in Interstitial Lung Disease
  • MTE26. How to Assess the Outcome of a Pulmonary Rehabilitation Programme?
  • MTE28. Progress in Progressive Pulmonary Fibrosis: An Update in Definition and Management
  • MTE32. Management of Immune Mediated Myositis Related Lung Disease in 2023
  • MTE37. Exercise Test in New Era: Updated Quality in Pulmonary Rehabilitation After COVID-19
  • MTE38. Refractory Sarcoidosis: When and How to Use TNF-Inhibitors
  • MTE42. Smoking Related Interstitial Lung Diseases
  • MTE43. Organs-On-Chips for the Lungs: Past, Current and Future
  • MTE49. Phenotyping Systemic Sclerosis Associated Pulmonary Hypertension
  • MTE51. Familial Pulmonary Fibrosis
  • MTE52. Leveraging Big Data to Bridge the Knowledge-Outcome Gaps in Rare Lung Disease
  • MTE54. Understanding Severe and Steroid-Refractory Immune Checkpoint Inhibitor Pneumonitis
  • MTE55. Running an Effective Interstitial Lung Disease Multidisciplinary Meeting: Reaching the Gold Standard
  • MTE56. Complex In Vitro Models of the Lung: Bridging the Gap Between Disease Complexity and Therapeutics
  • MTE58. Overview of Bronchiolar Disorders
  • MTE61. From Feathers to Antifibrotics: Exposures, Diagnosis, and Treatment in Hypersensitivity Pneumonitis

Register for ATS 2023

Register today for the ATS 2023 International Conference! Don’t miss this opportunity to take part in the in-person conference, May 19-24 in Washington, DC. Join your colleagues to learn about the latest developments in pulmonary, critical care, and sleep medicine.